Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Frontiers in Oncology(2024)
摘要
[This corrects the article DOI: 10.3389/fonc.2023.1247291.].
更多查看译文
关键词
endometrial cancer,molecular classification,immune checkpoint inhibitors,dostarlimab,pembrolizumab plus lenvatinib
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要